We want to save patients with severe cancer and autoimmune diseases

Clinical investigations with our lead antibody CAN04 to our proprietary target

Göran Forsberg, CEO

Safe Harbour Statement

The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia's current thinking with respect to future events and financial performance. Prospective statements only express the assessments and assumptions the company makes at the time of the presentation. These statements are well-considered, but the audience should note that, as with all prospective assessments, they are associated with risks and uncertainties.

CAN04 phase I clinical data at ESMO


1172P

A first-in-class, first-in-human phase I/IIa trial of CAN04, targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), in patients with solid tumors

BACKGROUND

METHODS

Study design

Patient population

RESULTS

Patient population

Safety

Biomarkers

Clinical efficacy data

Pharmacokinetics

CONCLUSIONS

References

Acknowledgements

cantargia

- **CAN04 has generally been well tolerated**
- **6 mg/kg is safe.**
- **Biomarker results support target engagement already after two doses of CAN04.**
- **In a heavily pre-treated patient population, 5 of 13 patients (38%) had SD. One patient with NSCLC had SD for 6 months.**

cantargia

IL-1 blockade in cancer- Recent supportive clinical data

CANTOS trial

- Canakinumab (Novartis)
- Reduced lung cancer incidence by 67 % and death by 77 %.



- Clinical validation of IL-1 pathway
- Cantargia's CAN04 has broader MOA

Canakinumab phase 3 trials

Adjuvant NSCLC
After surgery, no mets, placebo control
1500 patients, recruitment ongoing
Completion 2021/22

First line (CANOPY-1)
Untreated locally advanced/metastatic
Combination Pembro/Platinum doublet
627 patients, start Dec 2018
Completion 2021/22

Second line metastatic (CANOPY-2)
Previously treated loc adv/metastatic
Combination Docetaxel
240 patients, start Dec 2018
Completion 2021

Source clinicaltrials.gov

CAN04 (nidanilimab) vs Canakinumab







Canakinumab

- Antibody directed against one of the two IL-1 ligands, IL-1β

CAN04:

- Binds the common signaling receptor and counteracts both ligands
- Induce killing via the immune system (ADCC)



Medical need and IL1RAP





Size of each indication corresponds to annual deaths in USA

- Cantargia founded based on:
  - Discovery of IL1RAP on cancer cells
  - Antibodies against IL1RAP - antitumor effects
  - Patents on antibody therapy against IL1RAP
- Primary indications. NSCLC and pancreatic cancer
- Biomarker studies ongoing, identify patients most likely to respond
- Opportunity to expand development in additional cancer forms

CAN04 – CANFOUR clinical trial

Phase I/IIa trial - NSCLC and pancreatic cancer

- Norway, Denmark, Netherlands and Belgium
- Well renowned centres (Jules Bordet, Brussels; Erasmus Rotterdam, NKI, Amsterdam; Rigshospitalet, Copenhagen; Radiumhospitalet, Oslo)
- 16 patients treated, good safety
  - NSCLC, pancreatic cancer, colon cancer, triple negative breast cancer
- Phase IIa: focused on NSCLC and pancreatic cancer (appr 20 centres)
  - Monotherapy
  - Combination with standard therapy
    - NSCLC Cisplatin/Gemcitabine
    - Pancreatic cancer Gemcitabine/nab-paclitaxel



Q4 2018

Early 2020

Details on www.clinicaltrials.gov

Cantargia at a glance

- Specialized in antibody therapy/immunology, with initial focus on oncology
- Granted IP - therapeutic target IL1RAP and drug candidate
- Lead antibody CAN04 (nidanilimab) in clinical development
- Strong management team with proven track record in clinical development and business development
- Listed on Nasdaq Stockholm
- Approximately 5000 shareholders
- Based in Lund, Sweden

Financial highlights

- Share price: 19.90 SEK (2.22 USD), Oct 22, 2018
- Market cap: 1317 MSEK (147 MUSD), Oct 22, 2018
- Cash: 213 MSEK (23.3 MUSD), Jun 30 2018

Current owners (Sep 30, 2018)	
Sunstone	9.0%
1st AP fund	6.9%
Avanza Pension	5.2%
4th AP fund	4.6%
2nd AP fund	3.3%
Öhman Bank S.A.	3.3%
SEB S.A. clients	3.2%
Mats Invest AB	2.0%
Tibia konsult	1.9%
Kudu AB	1.9 %
Others	58.6%

Cantargia pipeline



CAN04 attacks several cell types in the tumor



NSCLC CAN04/Cisplatin combination



	Control	CAN04	Cisplatin	Combination
Animals withdrawn	20 % (Tumor)	0 %	50 % (Toxicity)	20 % (Toxicity)
Tumor reduction	N/A	14%	18%	52 %
Comment	*Highest tumor burden*	*Best safety*	*Highest toxicity*	*Superior efficacy and reduced toxicity*

Combination CAN04/Cisplatin superior to individual agents

- **Reduction in severe toxicity**
- **Increased efficacy**

Cantargia

Inflammation and metastasis

- Cancer cells (seeds) needs a good soil to form a metastasis
- The IL-1 system (inflammation) can provide such environment (soil)





A tumor can create its own ”seed and soil”

Cantargia

IL1RAP - additional potential indications to leverage the value of our asset

- Three different systems signal through IL1RAP
- These systems contribute to various inflammatory diseases
- Can be blocked by Cantargia's antibodies against IL1RAP



Cantargia partnership with Panorama Res Inc (Sunnyvale, CA)
Selection of clinical candidate 2019

Significant value inflection points ahead

2018

- Preclinical data (immuno-oncology effects, combinations etc)
- Phase I clinical data final dose level (Q4 2018)
- Initiation of Phase IIa portion of the clinical trial (Q4 2018)
- US regulatory and clinical strategy

2019/2020

- Clinical progress and Phase IIa results
- Preclinical progress
- CANxx progress

Cantargia summary

- Lead candidate antibody CAN04 in clinical trials against cancer
  - Encouraging interim phase I data
  - Double mechanism of action
  - Initial development in NSCLC and pancreatic cancer (cancer forms with poor prognosis)
  - Direct effects on tumor cells and tumor microenvironment
  - Recent external validation of pathway
- Second generation antibodies for autoimmune disease
- Unique and strong IP
- Strong lead investors with high competence and well known track record
  - Funding through phase IIa - until mid 2020.